<?xml version="1.0" encoding="UTF-8"?>
<p>The annual global drug market is worth about one trillion USD (Calixto, 
 <xref rid="B27" ref-type="bibr">2019</xref>). A comprehensive analysis of drugs approved by the United States' Food and Drug Administration (FDA) from 1981 to 2010 shows that ~35% of these drugs were directly or indirectly of natural products origin, including plants (25% of total new pharmaceuticals) (Newman and Cragg, 
 <xref rid="B77" ref-type="bibr">2012</xref>, 
 <xref rid="B78" ref-type="bibr">2016</xref>). Over the last two centuries, the global pharmaceutical industry has significantly profited from the biodiversity of several countries when it comes to identifying new therapeutics against important pathogens, especially the development of new chemotypes for managing protozoal diseases such as malaria and leishmaniasis (Calixto, 
 <xref rid="B27" ref-type="bibr">2019</xref>).
</p>
